DE69818106D1 - Immunologische zusammensetzungen und verfahren zur transienten änderung des zentralnervensystem-myelins der saügetiere und förderung der nerven-regenerierung - Google Patents

Immunologische zusammensetzungen und verfahren zur transienten änderung des zentralnervensystem-myelins der saügetiere und förderung der nerven-regenerierung

Info

Publication number
DE69818106D1
DE69818106D1 DE69818106T DE69818106T DE69818106D1 DE 69818106 D1 DE69818106 D1 DE 69818106D1 DE 69818106 T DE69818106 T DE 69818106T DE 69818106 T DE69818106 T DE 69818106T DE 69818106 D1 DE69818106 D1 DE 69818106D1
Authority
DE
Germany
Prior art keywords
transientally
myeline
mammals
modifying
immunological compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69818106T
Other languages
English (en)
Other versions
DE69818106T2 (de
Inventor
D Steeves
K Dyer
S Keirstead
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dyer Jason K Vancouver British Columbia Ca
Steeves John D Vancouver British Columbia Ca
Original Assignee
University of British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA 2219683 external-priority patent/CA2219683A1/en
Application filed by University of British Columbia filed Critical University of British Columbia
Application granted granted Critical
Publication of DE69818106D1 publication Critical patent/DE69818106D1/de
Publication of DE69818106T2 publication Critical patent/DE69818106T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69818106T 1997-10-28 1998-10-28 Immunologische zusammensetzungen und verfahren zur transienten änderung des zentralnervensystem-myelins der saügetiere und förderung der nerven-regenerierung Expired - Lifetime DE69818106T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CA 2219683 CA2219683A1 (en) 1997-10-28 1997-10-28 Immunological composition and its method of use to transiently disrupt mammalian central nervous system myelin to promote neuronal regeneration
CA2219683 1997-10-28
CA2251410 1998-10-16
CA2251410 1998-10-16
PCT/CA1998/000997 WO1999021581A1 (en) 1997-10-28 1998-10-28 Immunological compositions and methods of use to transiently alter mammalian central nervous system myelin to promote neuronal regeneration

Publications (2)

Publication Number Publication Date
DE69818106D1 true DE69818106D1 (de) 2003-10-16
DE69818106T2 DE69818106T2 (de) 2004-06-17

Family

ID=25679779

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69818106T Expired - Lifetime DE69818106T2 (de) 1997-10-28 1998-10-28 Immunologische zusammensetzungen und verfahren zur transienten änderung des zentralnervensystem-myelins der saügetiere und förderung der nerven-regenerierung

Country Status (11)

Country Link
US (2) US6969516B1 (de)
EP (1) EP1047449B1 (de)
JP (1) JP2001521008A (de)
AT (1) ATE249241T1 (de)
AU (1) AU748143B2 (de)
DE (1) DE69818106T2 (de)
DK (1) DK1047449T3 (de)
ES (1) ES2210829T3 (de)
IL (2) IL135799A0 (de)
PT (1) PT1047449E (de)
WO (1) WO1999021581A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4095900A (en) * 1999-04-28 2000-11-10 University Of British Columbia, The Composition for neuronal regeneration comprising myelin-specific antibodies and complement proteins
GB0103174D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Plc Novel method of treatment
TWI323265B (en) * 2002-08-06 2010-04-11 Glaxo Group Ltd Antibodies
GB0306309D0 (en) 2003-03-19 2003-04-23 Glaxo Group Ltd Method of treatment
ES2557056T3 (es) 2006-10-10 2016-01-21 Regenesance B.V. Inhibición del complemento para una mejor regeneración de los nervios
LT2649086T (lt) * 2010-12-09 2017-11-10 The Trustees Of The University Of Pennsylvania Chimeriniu antigenų receptoriumi modifikuotų ląstelių naudojimas vėžio gydymui
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
US10058471B2 (en) * 2014-02-21 2018-08-28 William M. Vaughan System and method of using hyperbaric oxygen therapy for treating concussive symptoms and musculoskeletal injuries and for pre-treatment to prevent damage from injuries
KR20240042250A (ko) 2014-04-07 2024-04-01 노파르티스 아게 항-cd19 키메라 항원 수용체를 사용한 암의 치료
KR20170134642A (ko) 2015-04-08 2017-12-06 노파르티스 아게 Cd20 요법, cd22 요법, 및 cd19 키메라 항원 수용체 (car) - 발현 세포와의 조합 요법
WO2018067992A1 (en) 2016-10-07 2018-04-12 Novartis Ag Chimeric antigen receptors for the treatment of cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991002003A1 (en) * 1989-08-04 1991-02-21 Board Of Regents, The University Of Texas System Methods and compositions; purified preparation of neural progenitor regulatory factor
US6020140A (en) * 1991-08-09 2000-02-01 Washington University Autoantibodies and their targets in the diagnosis of peripheral neuropathies
ATE187889T1 (de) * 1992-06-12 2000-01-15 Cephalon Inc Vorbeugung und behandlung der peripheren neuropathie
US5714385A (en) * 1995-05-10 1998-02-03 Genentech, Inc. Media for culturing schwann cells
US6228598B1 (en) * 1998-10-02 2001-05-08 Washington University Antibodies to heparan sulfate glycosaminoglycans in the diagnosis of polyneuropathies

Also Published As

Publication number Publication date
AU748143B2 (en) 2002-05-30
US6548061B1 (en) 2003-04-15
US6969516B1 (en) 2005-11-29
JP2001521008A (ja) 2001-11-06
DK1047449T3 (da) 2004-01-26
DE69818106T2 (de) 2004-06-17
WO1999021581A1 (en) 1999-05-06
IL135799A (en) 2011-01-31
IL135799A0 (en) 2001-05-20
ATE249241T1 (de) 2003-09-15
PT1047449E (pt) 2004-04-30
EP1047449A1 (de) 2000-11-02
EP1047449B1 (de) 2003-09-10
ES2210829T3 (es) 2004-07-01
AU9617998A (en) 1999-05-17

Similar Documents

Publication Publication Date Title
Narayanan et al. Biosynthesis and regulation of type V collagen in diploid human fibroblasts.
Coulter et al. Simplified preparation of rabbit Fab fragments
DE69818106D1 (de) Immunologische zusammensetzungen und verfahren zur transienten änderung des zentralnervensystem-myelins der saügetiere und förderung der nerven-regenerierung
Tenenhouse et al. Some physical-chemical properties of chicken γ-globulins and their pepsin and papain digestion products
Vaughan et al. Proteoglycan Lt from chicken embryo sternum identified as type IX collagen.
NL300372I1 (nl) Hybride immunoglobulinen voor gebruik bij therapeutische werkwijzen
ATE171042T1 (de) Verfahren und zusammensetzungen zur verbesserung der symptome von sepsis
DE68915675T2 (de) Verfahren zur Reinigung von Vitamin K-abhängigen Proteinen.
AR035786A2 (es) Variantes de factores de coagulacion dependientes de vitamina k y composiciones que los contienen
EA199801043A1 (ru) Антитела против домена ed-в в фибронектина, их конструирование и использование
MX7235E (es) Procedimiento para preparar una solucion inyectable intravenosamente de globulina de suero inmune
ATE170630T1 (de) Proteine mit geänderten epitopen und verfahren zur deren herstellung
Rapp et al. Constituents and antigens of normal human gastric mucosa as characterized by electrophoresis and immunoelectrophoresis in agar gel
DE69028513T2 (de) Träger zur bindung von antiphospholipid-antikörpern, diese antikörper verwendender immunotest und kit dafür
DK407488A (da) Fremgangsmaade til behandling af overskud af jern
SE7909488L (sv) Hemjernrikat aminosyrapreparat och forfarande for framstellning av hemjernrikade aminosyrapreparat fran hemproteiner
DE69330352T2 (de) Mittel und methoden zur verbesserung der keratinocytenadhäsion an der haut
Dehm et al. Antibodies to Chick‐Tendon Procollagen: Affinity Purification with the Isolated Disulfide‐Linked NH2‐Terminal Extensions and Reactivity with a Component in Embryonic Serum
Crofton Site of alkaline phosphatase attachment in alkaline phosphatase-immunoglobulin G complexes
EA199900522A1 (ru) Полипептиды, кодируемые геном, подобным гену липазы человека, композиции и методы
DE69432472D1 (de) Verfahren zur hemmung der phagozytose
DE3689177D1 (de) Verfahren zur Behandlung von Füllmaterialien und zur Konstruktion rutschfester Strassenoberflächen.
Harada et al. Inflammatory mediators and modulators released in organ culture from rabbit skin lesions produced in vivo by sulfur mustard. III. Electrophoretic protein fractions, trypsin-inhibitory capacity, alpha 1-proteinase inhibitor, and alpha 1-and alpha 2-macroglobulin proteinase inhibitors of culture fluids and serum.
DE69707229D1 (de) Verfahren zur Herstellung von Kohlenwasserstoffen reich an Mittendestillatfraktion
ATE37611T1 (de) Verfahren zur verringerung einer truebung in kontrollseren.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: STEEVES, JOHN D., VANCOUVER, BRITISH COLUMBIA, CA

Owner name: DYER, JASON K., VANCOUVER, BRITISH COLUMBIA, CA